It has been another eventful year for Professor Sir Michael Rawlins, who was reappointed as chair of the National Institute for Health and Clinical Excellence in March after a special exemption allowed him to extend his tenure.

Since last year’s publication of Lord Darzi’s review, NICE has continued to expand its remit, and this year created its first set of quality standards and quality and outcomes framework indicators. This April saw the launch of NHS Evidence, the one stop information portal. NICE inevitably courts controversy. It has been repeatedly slated in the media over its decision not to recommend certain cancer drugs and became embroiled in the US debate over President Obama’s healthcare reforms. However, when Sir Mike himself was given a grilling by The Northern Echo, he put the spotlight on greedy pharmaceutical companies that charge too much for new drugs. It is his unwavering defence of NICE that helped him secure another two years as its chair. He remains one of the most influential people in the NHS.